JP2019515899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515899A5 JP2019515899A5 JP2018553360A JP2018553360A JP2019515899A5 JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5 JP 2018553360 A JP2018553360 A JP 2018553360A JP 2018553360 A JP2018553360 A JP 2018553360A JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- agent
- dose
- human subject
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 210000001995 reticulocyte Anatomy 0.000 claims 6
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 5
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000037452 priming Effects 0.000 claims 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000012292 receptor occupancy assay Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140214A JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323330P | 2016-04-15 | 2016-04-15 | |
| US62/323,330 | 2016-04-15 | ||
| US201662427679P | 2016-11-29 | 2016-11-29 | |
| US62/427,679 | 2016-11-29 | ||
| PCT/US2017/027662 WO2017181033A1 (en) | 2016-04-15 | 2017-04-14 | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Division JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515899A JP2019515899A (ja) | 2019-06-13 |
| JP2019515899A5 true JP2019515899A5 (https=) | 2020-05-14 |
| JP7532009B2 JP7532009B2 (ja) | 2024-08-13 |
Family
ID=60042716
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553360A Active JP7532009B2 (ja) | 2016-04-15 | 2017-04-14 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472878B2 (https=) |
| EP (3) | EP3442578B1 (https=) |
| JP (3) | JP7532009B2 (https=) |
| KR (3) | KR20240016445A (https=) |
| CN (3) | CN115350276A (https=) |
| AU (2) | AU2017250809B2 (https=) |
| CA (1) | CA3019676A1 (https=) |
| ES (1) | ES2909835T3 (https=) |
| PL (1) | PL3442578T3 (https=) |
| PT (1) | PT3442578T (https=) |
| SI (1) | SI3442578T1 (https=) |
| WO (1) | WO2017181033A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| SI4177270T1 (sl) | 2017-10-18 | 2024-10-30 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
| AU2019218271B2 (en) * | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| CN119684457A (zh) | 2018-11-26 | 2025-03-25 | 四十七有限责任公司 | 针对c-kit的人源化抗体 |
| US20220023348A1 (en) | 2018-11-28 | 2022-01-27 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
| CN114786776B (zh) | 2019-09-18 | 2026-03-24 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| PE20230116A1 (es) * | 2020-04-06 | 2023-01-27 | Univ Leland Stanford Junior | Formulacion de anticuerpos |
| CA3194577A1 (en) * | 2020-10-09 | 2022-04-14 | Sonja SCHREPFER | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009205665B2 (en) | 2008-01-15 | 2013-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
| EP2249801A2 (en) * | 2008-02-07 | 2010-11-17 | Amgen Inc. | Stabilized protein compositions |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| CN105101997B (zh) | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| PT2970493T (pt) * | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| KR102175688B1 (ko) * | 2013-03-27 | 2020-11-06 | 제넨테크, 인크. | 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용 |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| WO2015050983A1 (en) | 2013-10-01 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules |
| ES3012974T3 (en) | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| WO2015189698A2 (en) * | 2014-06-08 | 2015-12-17 | Beijing Cosci-Remd Bio Med Tech Company Ltd | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| WO2016057980A1 (en) * | 2014-10-10 | 2016-04-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting cd47 |
| PE20230116A1 (es) * | 2020-04-06 | 2023-01-27 | Univ Leland Stanford Junior | Formulacion de anticuerpos |
-
2017
- 2017-04-14 AU AU2017250809A patent/AU2017250809B2/en active Active
- 2017-04-14 CN CN202210926503.6A patent/CN115350276A/zh active Pending
- 2017-04-14 PT PT177832540T patent/PT3442578T/pt unknown
- 2017-04-14 EP EP17783254.0A patent/EP3442578B1/en active Active
- 2017-04-14 CN CN202311544173.5A patent/CN117695387A/zh active Pending
- 2017-04-14 EP EP22155479.3A patent/EP4074339A1/en active Pending
- 2017-04-14 SI SI201731120T patent/SI3442578T1/sl unknown
- 2017-04-14 KR KR1020247002294A patent/KR20240016445A/ko active Pending
- 2017-04-14 WO PCT/US2017/027662 patent/WO2017181033A1/en not_active Ceased
- 2017-04-14 US US16/089,115 patent/US11472878B2/en active Active
- 2017-04-14 PL PL17783254T patent/PL3442578T3/pl unknown
- 2017-04-14 KR KR1020237006777A patent/KR20230035435A/ko not_active Ceased
- 2017-04-14 CA CA3019676A patent/CA3019676A1/en active Pending
- 2017-04-14 CN CN201780029157.9A patent/CN109152837A/zh active Pending
- 2017-04-14 JP JP2018553360A patent/JP7532009B2/ja active Active
- 2017-04-14 EP EP24159469.6A patent/EP4349412A3/en active Pending
- 2017-04-14 ES ES17783254T patent/ES2909835T3/es active Active
- 2017-04-14 KR KR1020187032126A patent/KR102505253B1/ko active Active
-
2022
- 2022-09-02 JP JP2022140214A patent/JP7442591B2/ja active Active
- 2022-09-08 US US17/930,621 patent/US11718670B2/en active Active
-
2023
- 2023-06-15 US US18/210,483 patent/US20230406923A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023723A patent/JP2024059764A/ja active Pending
- 2024-05-22 AU AU2024203396A patent/AU2024203396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515899A5 (https=) | ||
| JP7125932B2 (ja) | 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法 | |
| JP2018515493A5 (https=) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2012067116A5 (https=) | ||
| Hoeper et al. | Update in pulmonary hypertension 2005 | |
| JP2018535929A5 (https=) | ||
| CN106459971B (zh) | 用于治疗自身免疫性疾病的联合疗法 | |
| JP2021514003A5 (https=) | ||
| Pipitone et al. | Treatment of inflammatory myopathies | |
| Cohen et al. | Phase 2 studies of adenosine cardioplegia | |
| Son et al. | SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis | |
| JP2015013887A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| CN116390756A (zh) | 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 | |
| Patwardhan et al. | Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon | |
| CN107405413A (zh) | 使用smad7反义寡核苷酸的方法 | |
| JP2020510028A5 (https=) | ||
| Tedesco-Silva et al. | Open-label, randomized study of transition from tacrolimus to sirolimus immunosuppression in renal allograft recipients | |
| JP2023113870A (ja) | Ｂ因子阻害剤の使用方法 | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| US12594320B2 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| WO2019241742A1 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer | |
| RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Galeazzi et al. | SAT0196 Dekavil (F8-IL10), A Novel Therapeutic Approach for Rheumatoid Arthritis: Ongoing Phase IB Clinical Trial Results | |
| CN112190708A (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |